The Trump administration advanced federal marijuana policy through an April 2026 final order that moved FDA-approved cannabis products and state-licensed medical marijuana into Schedule III under the Controlled Substances Act, while leaving broader adult-use cannabis in Schedule I. A restarted DEA administrative hearing on full rescheduling to Schedule III ran from late June through mid-July 2026, after which the agency urged the administrative law judge to recommend the change based on accepted medical use and safety data. As of late August, the full hearing transcript was released and post-hearing briefs filed, with the judge now preparing a recommendation before the record moves to the DEA administrator for a potential final rule. The process carries no fixed statutory deadline, faces opposition from participating states and advocacy groups, and remains subject to ongoing D.C. Circuit litigation, creating uncertainty around any near-term expansion beyond the partial April action.